Price
$11.76
Increased by +0.09%
Dollar Volume (20D)
3.52 M
ADR%
5.42
Earnings Report Date (estimate)
Nov 13, 23 (-0.34)
Market Cap.
578.61 M
Shares Float
28.33 M
Shares Outstanding
49.20 M
Beta
1.27
Price / Earnings
-8.22
BPR
0.54
20D Range
11.31 13.63
50D Range
10.38 14.92
200D Range
5.81 14.92
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 14, 23 0.27
Increased by +145.00%
0.38
Decreased by -28.95%
May 11, 23 -0.28
Decreased by -12.00%
-0.37
Increased by +24.32%
Mar 23, 23 -0.41
Increased by +21.15%
-0.27
Decreased by -51.85%
Nov 14, 22 -0.42
Increased by +23.64%
-0.10
Decreased by -320.00%
Aug 11, 22 -0.60
Decreased by -30.43%
-0.39
Decreased by -53.85%
May 12, 22 -0.25
Increased by +44.44%
-0.19
Decreased by -31.58%
Mar 17, 22 -0.52
Decreased by -92.59%
-0.30
Decreased by -73.33%
Nov 10, 21 -0.55
Decreased by -96.43%
-0.00
Decreased by -11.10 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 8.59 M
Increased by +62.38%
-13.16 M
Increased by +27.31%
Decreased by -153.10%
Increased by +55.23%
Mar 31, 23 9.39 M
Decreased by -31.12%
-11.01 M
Decreased by -46.27%
Decreased by -117.29%
Decreased by -112.37%
Dec 31, 22 2.78 M
Decreased by -38.72%
-18.86 M
Decreased by -24.38%
Decreased by -679.54%
Decreased by -102.96%
Sep 30, 22 8.37 M
Decreased by -1.75%
-12.71 M
Increased by +5.78%
Decreased by -151.95%
Increased by +4.10%
Jun 30, 22 5.29 M
Decreased by -26.43%
-18.10 M
Decreased by -64.09%
Decreased by -341.99%
Decreased by -123.04%
Mar 31, 22 13.63 M
Increased by +325.37%
-7.53 M
Increased by +29.28%
Decreased by -55.23%
Increased by +83.37%
Dec 31, 21 4.53 M
Decreased by -19.72%
-15.17 M
Decreased by -139.15%
Decreased by -334.81%
Decreased by -197.91%
Sep 30, 21 8.52 M
Increased by +345.16%
-13.49 M
Decreased by -119.88%
Decreased by -158.45%
Increased by +50.61%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.